RxDoctor Payments Data

Aisha Afzal, MD

Internal Medicine · Troy, MINPI 1538474440

Payments from drug & device makers

$1,425in general payments, 2019–2025

Across 16 payments — averaging $89.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$1K
  • Neurocrine Biosciences, Inc.$125
  • Pfizer$102
  • GSK$34
  • Johnson & Johnson$29
  • Alkermes, Inc.$19
  • plus $17 from 1 others

What the payments were for

  • Travel & lodging$68248%
  • Food & beverage$74352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,425 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$268,183
Medicare patients
335
Services billed
2,334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban214$65,445
JardianceEmpagliflozin84$25,539
RenvelaSevelamer Carbonate20$14,548
Formoterol Fumarate23$14,413
JanuviaSitagliptin Phosphate47$13,744
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$9,576
LokelmaSodium Zirconium Cyclosilicate22$8,402
Midodrine Hcl68$8,298
TrulicityDulaglutide16$8,153
LinzessLinaclotide12$6,992
Incruse ElliptaUmeclidinium Bromide18$6,792
EntrestoSacubitril/Valsartan14$5,997
XareltoRivaroxaban18$5,840
Budesonide30$5,300
Mirtazapine132$4,568

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$102$65,445214 claims
GSKTrelegy Ellipta, Incruse Ellipta$34$16,36835 claims
AbbVieLinzess$17$6,99212 claims
Johnson & JohnsonXarelto$29$5,84018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Troy

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →